Rimifin (12,5 - 25 kg)
Wirkstoff
ATC-Code
Tierarten
Dogs.
Diagnosen
In the dog:
Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain.
Wartezeit
Not applicable.
Dosierung und Art der Anwendung
For oral administration.
2 to 4 mg carprofen per kg bodyweight per day.
An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses may, subject to clinical response, be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose.
Duration of treatment will be dependant upon the response seen. Long term treatment should be under regular veterinary supervision.
To extend analgesic and anti-inflammatory cover post-operatively, parenteral preoperative treatment may be followed with Carprofen tablets at 4 mg/kg/day for up to 5 days.
Do not exceed the stated dose.
Nebenwirkungen
Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.
As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)
Literaturhinweis
VERIFIZIERTE DATEN
| STATUS | Im Handel verfügbar |
|---|
